Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†.

Horwich A, Babjuk M, Bellmunt J, Bruins HM, Reijke TM, Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, Bari B, Blok W, De Visschere PJL, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, Oyen WJG, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Witjes JA.

Ann Oncol. 2019 Nov 19. pii: mdz296. doi: 10.1093/annonc/mdz296. [Epub ahead of print]

PMID:
31740927
2.

Lifetime Transfusion Burden and Transfusion-Related Iron Overload in Adult Survivors of Solid Malignancies.

Woei-A-Jin FJSH, Zheng SZ, Kiliçsoy I, Hudig F, Luelmo SAC, Kroep JR, Lamb HJ, Osanto S.

Oncologist. 2019 Aug 27. pii: theoncologist.2019-0222. doi: 10.1634/theoncologist.2019-0222. [Epub ahead of print]

PMID:
31455748
3.

Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting.

Aluwini SS, Mehra N, Lolkema MP, Oprea-Lager DE, Yakar D, Stoevelaar H, van der Poel H; Dutch Oligometastatic Prostate Cancer Working Group, Busstra M, de Jong IJ, de Reijke T, de Vries K, Heijmink S, Jenster G, Klaver S, Kneppers J, Lavalaye J, Leyten G, Moonen L, Nagaraj J, Noordzij W, Osanto S, Oving I, Schaake E, Scheenen T, Schoots I, Sedelaar M, Somford D, van den Berkmortel F, van der Hulle T, van der Voort van Zyp J, van Leeuwen P, van Moorselaar J, van Oort I, Vogel W, Westgeest H.

Eur Urol Oncol. 2019 Aug 7. pii: S2588-9311(19)30113-0. doi: 10.1016/j.euo.2019.07.010. [Epub ahead of print]

PMID:
31401014
4.

Discussing Sexual Health in the Medical Oncologist's Practice: Exploring Current Practice and Challenges.

Krouwel EM, Albers LF, Nicolai MPJ, Putter H, Osanto S, Pelger RCM, Elzevier HW.

J Cancer Educ. 2019 Jun 17. doi: 10.1007/s13187-019-01559-6. [Epub ahead of print]

PMID:
31209770
5.

Dose Reduction May Jeopardize Efficacy of Abiraterone Acetate.

Woei-A-Jin FJSH, Van Nieuwenhuyse T, van Erp NP, Beuselinck B, Stroobants S, Moes DJAR, Osanto S, Spriet I.

J Clin Oncol. 2018 Oct 20;36(30):3062-3064. doi: 10.1200/JCO.2018.79.3182. Epub 2018 Sep 6. No abstract available.

PMID:
30188790
6.

Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience.

Osanto S, van der Hulle T.

Ther Adv Urol. 2018 Jan 9;10(3):109-123. doi: 10.1177/1756287217748867. eCollection 2018 Mar. Review.

7.

CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.

Karkampouna S, van der Helm D, Gray PC, Chen L, Klima I, Grosjean J, Burgmans MC, Farina-Sarasqueta A, Snaar-Jagalska EB, Stroka DM, Terracciano L, van Hoek B, Schaapherder AF, Osanto S, Thalmann GN, Verspaget HW, Coenraad MJ, Kruithof-de Julio M.

J Pathol. 2018 Jul;245(3):297-310. doi: 10.1002/path.5083. Epub 2018 May 9.

PMID:
29604056
8.

International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer.

van Leeuwen M, Kieffer JM, Efficace F, Fosså SD, Bolla M, Collette L, Colombel M, De Giorgi U, Holzner B, van de Poll-Franse LV, van Poppel H, White J, de Wit R, Osanto S, Aaronson NK; European Organisation for Research and Treatment of Cancer Quality of Life Group; Genito-Urinary Cancers Group and Radiation Oncology Group; and the NCRN Testis Clinical Studies Group.

Health Qual Life Outcomes. 2017 May 11;15(1):97. doi: 10.1186/s12955-017-0670-4.

9.

Fertility preservation counselling in Dutch Oncology Practice: Are nurses ready to assist physicians?

Krouwel EM, Nicolai MPJ, van Steijn-van Tol AQMJ, Putter H, Osanto S, Pelger RCM, Elzevier HW.

Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12614. Epub 2016 Dec 27.

PMID:
28026055
10.

Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis?

Woei-A-Jin FJ, Tesselaar ME, Garcia Rodriguez P, Romijn FP, Bertina RM, Osanto S.

Br J Cancer. 2016 Jul 26;115(3):332-8. doi: 10.1038/bjc.2016.170. Epub 2016 Jul 12.

11.

Adherence to guideline recommendations for management of clinical T1 renal cancers in the Netherlands: a population-based study.

Aben KK, Osanto S, Hulsbergen-van de Kaa CA, Soetekouw PM, Stemkens D, Bex A.

World J Urol. 2016 Aug;34(8):1053-60. doi: 10.1007/s00345-016-1841-3. Epub 2016 May 13.

12.

Addressing changed sexual functioning in cancer patients: A cross-sectional survey among Dutch oncology nurses.

Krouwel EM, Nicolai MP, van Steijn-van Tol AQ, Putter H, Osanto S, Pelger RC, Elzevier HW.

Eur J Oncol Nurs. 2015 Dec;19(6):707-15. doi: 10.1016/j.ejon.2015.05.005. Epub 2015 Jun 6.

PMID:
26051072
13.

Changes in bone mineral density in newly diagnosed testicular cancer patients after anticancer treatment.

Willemse PM, Hamdy NA, de Kam ML, Burggraaf J, Osanto S.

J Clin Endocrinol Metab. 2014 Nov;99(11):4101-8. doi: 10.1210/jc.2014-1722. Epub 2014 Aug 13.

PMID:
25119312
14.

Evaluation of lecithinized human recombinant super oxide dismutase as cardioprotectant in anthracycline-treated breast cancer patients.

Broeyer FJ, Osanto S, Suzuki J, de Jongh F, van Slooten H, Tanis BC, Bruning T, Bax JJ, Ritsema van Eck HJ, de Kam ML, Cohen AF, Mituzhima Y, Burggraaf J.

Br J Clin Pharmacol. 2014 Nov;78(5):950-60. doi: 10.1111/bcp.12429.

15.

Recruiting long-term survivors of European Organisation for Research and Treatment of Cancer phase III clinical trials into quality of life studies: challenges and opportunities.

van Leeuwen M, Efficace F, Fosså SD, Bolla M, De Giorgi U, de Wit R, Holzner B, van de Poll-Franse LV, van Poppel H, White J, Collette L, Osanto S, Aaronson NK; European Organisation for Research and Treatment of Cancer Quality of Life Group; Genito-Urinary Cancers Group; Radiation Oncology Group.

Eur J Cancer. 2014 Jul;50(11):1957-63. doi: 10.1016/j.ejca.2014.04.018. Epub 2014 May 9.

PMID:
24820932
16.

Procoagulant tissue factor activity on microparticles is associated with disease severity and bacteremia in febrile urinary tract infections.

Woei-A-Jin FJ, van der Starre WE, Tesselaar ME, Garcia Rodriguez P, van Nieuwkoop C, Bertina RM, van Dissel JT, Osanto S.

Thromb Res. 2014 May;133(5):799-803. doi: 10.1016/j.thromres.2014.03.007. Epub 2014 Mar 6.

PMID:
24657035
17.

Cryo-electron microscopy of extracellular vesicles in fresh plasma.

Yuana Y, Koning RI, Kuil ME, Rensen PC, Koster AJ, Bertina RM, Osanto S.

J Extracell Vesicles. 2013 Dec 31;2. doi: 10.3402/jev.v2i0.21494. eCollection 2013 Dec 31.

18.

Durable remission of renal cell carcinoma in conjuncture with graft versus host disease following allogeneic stem cell transplantation and donor lymphocyte infusion: rule or exception?

van Bergen CA, Verdegaal EM, Honders MW, Hoogstraten C, Steijn-van Tol AQ, de Quartel L, de Jong J, Meyering M, Falkenburg JH, Griffioen M, Osanto S.

PLoS One. 2014 Jan 15;9(1):e85198. doi: 10.1371/journal.pone.0085198. eCollection 2014.

19.

Reply: Comment on 'Chemotherapy for testicular cancer induces acute alterations in diastolic heart function'.

van Schinkel LD, Willemse PM, van der Meer RW, Burggraaf J, van Elderen SG, Smit JW, de Roos A, Osanto S, Lamb HJ.

Br J Cancer. 2014 Jan 7;110(1):265. doi: 10.1038/bjc.2013.704. Epub 2013 Nov 7. No abstract available.

20.

Outcome after ST elevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention.

Velders MA, Boden H, Hofma SH, Osanto S, van der Hoeven BL, Heestermans AA, Cannegieter SC, Jukema JW, Umans VA, Schalij MJ, van Boven AJ.

Am J Cardiol. 2013 Dec 15;112(12):1867-72. doi: 10.1016/j.amjcard.2013.08.019. Epub 2013 Sep 21.

PMID:
24063839
21.

Reply: 'Comment on Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors'.

Willemse PM, Burggraaf J, Hamdy NA, Osanto S.

Br J Cancer. 2013 Oct 29;109(9):2503-4. doi: 10.1038/bjc.2013.567. Epub 2013 Sep 17. No abstract available.

22.

Tasquinimod: a novel drug in advanced prostate cancer.

Osanto S, van Poppel H, Burggraaf J.

Future Oncol. 2013 Sep;9(9):1271-81. doi: 10.2217/fon.13.136.

23.

Penile cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Van Poppel H, Watkin NA, Osanto S, Moonen L, Horwich A, Kataja V; ESMO Guidelines Working Group.

Ann Oncol. 2013 Oct;24 Suppl 6:vi115-24. doi: 10.1093/annonc/mdt286. Epub 2013 Aug 23. No abstract available.

PMID:
23975666
24.

Abdominal visceral and subcutaneous fat increase, insulin resistance and hyperlipidemia in testicular cancer patients treated with cisplatin-based chemotherapy.

Willemse PM, van der Meer RW, Burggraaf J, van Elderen SG, de Kam ML, de Roos A, Lamb HJ, Osanto S.

Acta Oncol. 2014 Mar;53(3):351-60. doi: 10.3109/0284186X.2013.819116. Epub 2013 Aug 19.

PMID:
23957624
25.

Chemotherapy for testicular cancer induces acute alterations in diastolic heart function.

van Schinkel LD, Willemse PM, van der Meer RW, Burggraaf J, van Elderen SG, Smit JW, de Roos A, Osanto S, Lamb HJ.

Br J Cancer. 2013 Aug 20;109(4):891-6. doi: 10.1038/bjc.2013.445. Epub 2013 Aug 6.

26.

Alternatively spliced tissue factor promotes breast cancer growth in a β1 integrin-dependent manner.

Kocatürk B, Van den Berg YW, Tieken C, Mieog JS, de Kruijf EM, Engels CC, van der Ent MA, Kuppen PJ, Van de Velde CJ, Ruf W, Reitsma PH, Osanto S, Liefers GJ, Bogdanov VY, Versteeg HH.

Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):11517-22. doi: 10.1073/pnas.1307100110. Epub 2013 Jun 25.

27.

Patient with two secondary somatic-type malignancies in a late recurrence of a testicular non-seminoma: illustration of potential and flaw of the cancer stem cell therapy concept.

Oosterhuis JW, Peeters SH, Smit VT, Stoop H, Looijenga LH, Elzevier HW, Osanto S.

Int J Dev Biol. 2013;57(2-4):153-7. doi: 10.1387/ijdb.130141jo.

28.

Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors.

Willemse PM, Burggraaf J, Hamdy NA, Weijl NI, Vossen CY, van Wulften L, van Steijn-van Tol AQ, Rosendaal FR, Osanto S.

Br J Cancer. 2013 Jul 9;109(1):60-7. doi: 10.1038/bjc.2013.226. Epub 2013 May 9. Erratum in: Br J Cancer. 2013 Jul 9;109(1):295-6.

29.

Reply: Seminoma stage 1: Patterns of care in Europe.

Osanto S, Vossen C, Horwich A, Daugaard G, Van Poppel H.

BJU Int. 2013 Mar;111(3):E11-2. doi: 10.1111/bju.12020_5. No abstract available.

30.

Microparticle-associated tissue factor activity in plasma is unaffected by cytolytic chemotherapy treatment in metastatic testicular cancer patients.

van den Hengel LG, van Steijn-van Tol AQ, Bertina RM, Versteeg HH, Osanto S.

Thromb Res. 2013 Feb;131(2):187-9. doi: 10.1016/j.thromres.2012.11.026. Epub 2012 Dec 20. No abstract available.

PMID:
23260444
31.

Murine tissue factor coagulant activity is critically dependent on the presence of an intact allosteric disulfide.

van den Hengel LG, Osanto S, Reitsma PH, Versteeg HH.

Haematologica. 2013 Jan;98(1):153-8. doi: 10.3324/haematol.2012.069997. Epub 2012 Jul 16.

32.

Genome-wide microRNA expression analysis of clear cell renal cell carcinoma by next generation deep sequencing.

Osanto S, Qin Y, Buermans HP, Berkers J, Lerut E, Goeman JJ, van Poppel H.

PLoS One. 2012;7(6):e38298. doi: 10.1371/journal.pone.0038298. Epub 2012 Jun 20.

33.

Microparticles expressing tissue factor are concurrently released with markers of inflammation and coagulation during human endotoxemia.

Woei-A-Jin FJ, De Kruif MD, Garcia Rodriguez P, Osanto S, Bertina RM.

J Thromb Haemost. 2012 Jun;10(6):1185-8. doi: 10.1111/j.1538-7836.2012.04733.x. No abstract available.

34.

Patterns of care in the management of seminoma stage I: results from a European survey.

Vossen CY, Horwich A, Daugaard G, van Poppel H, Osanto S.

BJU Int. 2012 Aug;110(4):524-31. doi: 10.1111/j.1464-410X.2011.10887.x. Epub 2012 Mar 12.

35.

Determination of the size distribution of blood microparticles directly in plasma using atomic force microscopy and microfluidics.

Ashcroft BA, de Sonneville J, Yuana Y, Osanto S, Bertina R, Kuil ME, Oosterkamp TH.

Biomed Microdevices. 2012 Aug;14(4):641-9. doi: 10.1007/s10544-012-9642-y.

36.

Use of immuno-magnetic beads for direct capture of nanosized microparticles from plasma.

Yuana Y, Osanto S, Bertina RM.

Blood Coagul Fibrinolysis. 2012 Apr;23(3):244-50. doi: 10.1097/MBC.0b013e3283502924.

PMID:
22343682
37.

Deep-sequencing analysis reveals that the miR-199a2/214 cluster within DNM3os represents the vast majority of aberrantly expressed microRNAs in Sézary syndrome.

Qin Y, Buermans HP, van Kester MS, van der Fits L, Out-Luiting JJ, Osanto S, Willemze R, Vermeer MH, Tensen CP.

J Invest Dermatol. 2012 May;132(5):1520-2. doi: 10.1038/jid.2011.481. Epub 2012 Feb 16. No abstract available.

38.

Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial.

Porta C, Calvo E, Climent MA, Vaishampayan U, Osanto S, Ravaud A, Bracarda S, Hutson TE, Escudier B, Grünwald V, Kim D, Panneerselvam A, Anak O, Motzer RJ.

Eur Urol. 2012 Apr;61(4):826-33. doi: 10.1016/j.eururo.2011.12.057. Epub 2012 Jan 5.

39.

[The Dutch guideline 'Renal cell carcinoma'].

Osanto S, Bex A, Hulsbergen-van de Kaa CA, Soetekouw PM, Stemkens D.

Ned Tijdschr Geneeskd. 2012;156(5):A4462. Review. Dutch.

PMID:
22296904
40.

Emerging novel therapies for advanced prostate cancer.

Osanto S, Van Poppel H.

Ther Adv Urol. 2012 Feb;4(1):3-12. doi: 10.1177/1756287211432777.

41.

Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study.

Mulders P, Hawkins R, Nathan P, de Jong I, Osanto S, Porfiri E, Protheroe A, van Herpen CM, Mookerjee B, Pike L, Jürgensmeier JM, Gore ME.

Eur J Cancer. 2012 Mar;48(4):527-37. doi: 10.1016/j.ejca.2011.12.022. Epub 2012 Jan 28.

PMID:
22285180
42.

The relationship between tissue factor and cancer progression: insights from bench and bedside.

van den Berg YW, Osanto S, Reitsma PH, Versteeg HH.

Blood. 2012 Jan 26;119(4):924-32. doi: 10.1182/blood-2011-06-317685. Epub 2011 Nov 7. Review.

PMID:
22065595
43.

Advanced seminoma and nonseminoma: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009.

Schmoll HJ, Osanto S, Kawai K, Einhorn L, Fizazi K.

Urology. 2011 Oct;78(4 Suppl):S456-68. doi: 10.1016/j.urology.2011.08.001.

PMID:
21986225
44.

Current vaccination strategies for prostate cancer.

Joniau S, Abrahamsson PA, Bellmunt J, Figdor C, Hamdy F, Verhagen P, Vogelzang NJ, Wirth M, Van Poppel H, Osanto S.

Eur Urol. 2012 Feb;61(2):290-306. doi: 10.1016/j.eururo.2011.09.020. Epub 2011 Oct 3. Review.

PMID:
22001436
45.

Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies.

Escudier B, Osanto S, Ljungberg B, Porta C, Wagstaff J, Mulders P, Gore M, Bex A, Bellmunt J, Bracarda S, Franklin A, Honoré PH, Ravaud A, Steijn Jv, Aziz Z, Akaza H.

Cancer Treat Rev. 2012 Apr;38(2):127-32. doi: 10.1016/j.ctrv.2011.05.006. Review.

PMID:
21689888
46.

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.

Porta C, Osanto S, Ravaud A, Climent MA, Vaishampayan U, White DA, Creel P, Dickow B, Fischer P, Gornell SS, Meloni F, Motzer RJ.

Eur J Cancer. 2011 Jun;47(9):1287-98. doi: 10.1016/j.ejca.2011.02.014. Epub 2011 Apr 8. Review.

PMID:
21481584
47.

Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha.

Verdegaal EM, Visser M, Ramwadhdoebé TH, van der Minne CE, van Steijn JA, Kapiteijn E, Haanen JB, van der Burg SH, Nortier JW, Osanto S.

Cancer Immunol Immunother. 2011 Jul;60(7):953-63. doi: 10.1007/s00262-011-1004-8. Epub 2011 Mar 24.

48.

Pre-analytical and analytical issues in the analysis of blood microparticles.

Yuana Y, Bertina RM, Osanto S.

Thromb Haemost. 2011 Mar;105(3):396-408. doi: 10.1160/TH10-09-0595. Epub 2010 Dec 21. Review.

PMID:
21174005
49.

Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma.

Auwerda JJ, Yuana Y, Osanto S, de Maat MP, Sonneveld P, Bertina RM, Leebeek FW.

Thromb Haemost. 2011 Jan;105(1):14-20. doi: 10.1160/TH10-03-0187. Epub 2010 Nov 5.

PMID:
21057704
50.

Quantitative expression profiling of G-protein-coupled receptors (GPCRs) in metastatic melanoma: the constitutively active orphan GPCR GPR18 as novel drug target.

Qin Y, Verdegaal EM, Siderius M, Bebelman JP, Smit MJ, Leurs R, Willemze R, Tensen CP, Osanto S.

Pigment Cell Melanoma Res. 2011 Feb;24(1):207-18. doi: 10.1111/j.1755-148X.2010.00781.x. Epub 2010 Oct 21.

PMID:
20880198

Supplemental Content

Loading ...
Support Center